Brief: Nymox Reports Safety Benefits Of Fexapotide Treatments For Prostate Cancer And Benign Prostatic Hyperplasia
03/10/2018 17:13
Oct 3 (Reuters) - Nymox Pharmaceutical Corp NYMX.O :
* NYMOX REPORTS SAFETY BENEFITS OF FEXAPOTIDE TREATMENTS FOR
PROSTATE CANCER AND BENIGN PROSTATIC HYPERPLASIA
* NYMOX PHARMACEUTICAL CORP - NO IDENTIFIABLE RISKS OR
SERIOUS
SIDE EFFECTS OR ADVERSE EVENTS IDENTIFIED ASSOCIATED OR LINKED
WITH FT
Source text for Eikon: ID:nGNXZ4sH2
Further company coverage: NYMX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nymox Pharmaceutical
See all newsBrief: Nymox Says Required To Resubmit Application To DKMA
Brief: Nymox Pharmaceutical Corp Says Terminated Employment Of Christopher R Riley As CFO (June 27)
Brief: Nymox Announces Appointment Of Christopher R. Riley As Chief Financial Officer
Brief: Nymox Appeals Deficiency Letter
U.S. STOCKS ON THE MOVE-Pot stocks, Nymox, Zynerba